In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|October 6, 2021
Moderna Opens New Science Center in Cambridge, MA
Author(s)BioPharm International Editors
Moderna’s new 462,000-ft² science center is expected to be completed by 2023.
Advertisement
On Sept. 30, 2021, Moderna announced that it would be opening the Moderna Science Center in Cambridge, Massachusetts. The 462,000-ft² facility is designed to support Moderna’s continued growth in the messenger RNA (mRNA) medicine sector.
“We have been located in Massachusetts since our founding more than 10 years ago and are proud to be based here,”said Stéphane Bancel, CEO of Moderna, in a company press release. “As we advance our mRNA platform and science, our new science center will integrate digital-first scientific research and development labs along with space for innovation and co-creation with our people and our partners around the world.”
The new building will include custom spaces for research and development, but will also integrate non-scientific spaces to maximize collaboration and innovation. Construction led by Moderna’s long-term partner Alexandria Real Estate Equities has begun, with an expected move-in occurring in 2023.
Moderna highlighted sustainability when discussing the new building. The company is targeting Leadership in Energy and Environmental Design (LEED) Platinum Core & Shell and LEED Zero Energy certifications for the building. According to the press release, Moderna hopes that this site will be the most sustainable commercial lab building in Cambridge. To facilitate these goals, the building will include “ultra-efficient systems” as well as acoustical and light pollution mitigation measures.
“Our commitment to sustainability and accessibility requires us to think differently about space. Even as we grow, we are committed to minimizing our environmental footprint,” said Bancel in the press release. “We will continue to invest in the local economy, work with state and community partners, and leverage the incredible innovation to attract and grow the best talent from the Massachusetts life sciences sector as we work to deliver on the promise of mRNA science.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5